Study Information
Study Details
View study details on clinicaltrials.gov.
Locations
Clinical Trial FAQs
Information for patients and study volunteers, including frequently asked questions.
Description
This is a pilot study using [18F]F AraG PET imaging to evaluate the immunological response to checkpoint inhibitor therapy (CkIT) in patients with advanced NSCLC tumors at multiple study sites. The main objectives of the study are to quantify the change in [18F]F AraG PET signal before and after CkIT therapy, and to correlate this change in [18F]F AraG PET signal with a radiographic response.
Location: SIMR (Sacramento/Valley Area)
Please contact: SIMR@sutterhealth.org
Principal Investigator
Related Studies
Cancer Liquid Biopsy Monitoring Study
Investigators: Mohammed Kashani-Sabet, M.D., Deepti Behl, MD
COVID-19 Impacts on Cancer Care Management, Patient Experience and Care Costs
Investigators: Cheryl Stults, Ph.D., Monique de Bruin, M.D., MPH, Su-Ying Liang, Ph.D.
Stupski Serious Illness Program Evaluation
Investigator: Sylvia Sudat, PhD
Impact of COVID-19 on Cancer Care Management
Investigators: Su-Ying Liang, Ph.D., Monique de Bruin, M.D., MPH
Coverage, Price, and Reimbursement for Multigene Tests for Cancer and Related Conditions
Investigator: Su-Ying Liang, Ph.D.
Improving Cancer Care
Investigator: Su-Ying Liang, Ph.D.
Multilevel Study of Lung Cancer Screening Guidelines Implementation (MUST)
Investigator: Jiang Li, Ph.D., MPH
Implementing Universal Lynch Syndrome Screening Across Multiple Healthcare Systems: Identifying Strategies to Facilitate and Maintain Programs in Different Organizations Contexts
Investigators: Monique de Bruin, M.D., MPH, Su-Ying Liang, Ph.D., External PI, Principal Investigator
Lung Cancer in Never Smokers: Incidence, Risk Factors and Molecular Characteristics in Asian American, Native Hawaiian, and Pacific Islander (AANHPI) Women
Investigators: External PI, Principal Investigator, Su-Ying Liang, Ph.D.